首页|患者体验数据应用于药物真实世界研究的价值、方法与挑战

患者体验数据应用于药物真实世界研究的价值、方法与挑战

扫码查看
"以患者为中心"的药品监管理念下,在真实世界证据中纳入患者维度的评价愈显重要.患者体验数据可以补充和解释已有数据、生成直接来自患者的证据,实现药物研发中的患者参与.数据类型包括患者报告结局、自由文本类数据等,可通过自主收集或数据库获取.应用场景涉及新药注册、安全性评价、新增适应证等.在我国,将患者体验数据应用于真实世界研究主要面临以下挑战:缺乏收集高质量数据的条件、标准、动力,数据类型单一,数据安全与数据自由难以平衡等.建议我国出台专项指南、建立测量工具认证程序、拓展数据收集途径、探索数据源整合方法、优化知情同意机制、建立证据协同机制,以推动"以患者为中心"理念在药物真实世界研究中的实践应用.
Value,methods and challenges of applying patient experience data in real-world study of drugs
Under the "patient-centered" drug regulation concept,the inclusion of patient dimensions in real-world evidence becomes increasingly important. Patient experience data can complement and interpret existing data,generate evidence directly from patients,and achieve patient participation in drug development. Data types include patient-reported outcomes and free-text data,which can be collected autonomously or obtained from databases. Application scenarios involve new drug registration,safety evaluation,and additional indications. In China,applying patient experience data to real-world study mainly faces the following challenges:lack of conditions,standards,and motivation to collect high-quality data,a single type of data,and the difficulty of balancing data security with freedom,etc. It is recommended to issue special guidelines,establish a measurement tool certification process,expand data collection channels,explore data source integration methods,optimize the informed consent mechanism,and establish an evidence synergy mechanism to promote the practical application of the "patient-centered" concept in real-world study of drugs.

patient experience datareal-world studyregulatory decision-makingpatient-reported outcome

张乐乐、朱可盈、王端宁、何玉莹、丁佐奇

展开 >

中国药科大学国际医药商学院,南京 211198

患者体验数据 真实世界研究 监管决策 患者报告结局

2024

中国药房
中国医院协会,中国药房杂志社

中国药房

CSTPCD北大核心
影响因子:0.956
ISSN:1001-0408
年,卷(期):2024.35(23)